Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients

Journal of Clinical Investigation

Volumn 125, Issue 5, 2015, Pages 1979-1986

  Wild, Edward J ^a   Boggio, Roberto ^b,g   Langbehn, Douglas ^c   Robertson, Nicola ^a   Haider, Salman ^a   Miller, James R C ^a   Zetterberg, Henrik ^a,d   Leavitt, Blair R ^e   Kuhn, Rainer ^b,h   Tabrizi, Sarah J ^a   Macdonald, Douglas ^f   Weiss, Andreas ^b,h  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IRBM   (Italy)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f CHDI MANAGEMENT CHDI FOUNDATION   (United States)

^g Istituto di Ricerche Biomediche Antoine Marxer SpA   (Italy)

^h EVOTEC AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN; MUTANT HUNTINGTIN; MUTANT PROTEIN; NEUROFILAMENT PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG; HTT PROTEIN, HUMAN; HYBRID PROTEIN; MAPT PROTEIN, HUMAN; NERVE PROTEIN; NEUROFILAMENT PROTEIN L;

ADULT; ARTICLE; CAG REPEAT; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; HUNTINGTON CHOREA; IMMUNOASSAY; LIGHT CHAIN; MALE; MOTOR DYSFUNCTION; PRIORITY JOURNAL; PROBABILITY; SINGLE MOLECULE COUNTING IMMUNOASSAY; AGED; CANADA; GENETICS; HETEROZYGOTE DETECTION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; ONSET AGE; PROCEDURES; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE; TRINUCLEOTIDE REPEAT; UNITED KINGDOM;

ADULT; AGE OF ONSET; AGED; BRITISH COLUMBIA; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HETEROZYGOTE DETECTION; HUMANS; HUNTINGTON DISEASE; IMMUNOASSAY; LONDON; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; NEUROFILAMENT PROTEINS; RECOMBINANT FUSION PROTEINS; SENSITIVITY AND SPECIFICITY; SINGLE-BLIND METHOD; TAU PROTEINS; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84929012551     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI80743     Document Type: Article

References (34)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72(6):971-983.
2. Ross CA, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol. 2014;10(4):204-216.
3. Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10(1):83-98.
4. Wild EJ, Tabrizi SJ. Targets for future clinical trials in Huntington's disease: what's in the pipeline? Mov Disord. 2014;29(11):1434-1445.
5. Wexler NS, et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A. 2004;101(10):3498-3503.
6. Shi M, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol. 2011;69(3):570-580.
7. Miller TM, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12(5):435-442.
8. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131-144.
9. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem. 1996;67(5):2013-2018.
10. Weiss A, et al. Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. J Clin Invest. 2012;122(10):3731-3736.
11. Weiss A, et al. Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington's disease. Anal Biochem. 2009;395(1):8-15.
12. Macdonald D, et al. Quantification assays for total and polyglutamine-expanded huntingtin proteins. PLoS One. 2014;9(5):e96854.
13. Ko J, Ou S, Patterson PH. New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins. Brain Res Bull. 2001;56(3-4):319-329.
14. Penney JB Jr, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol. 1997;41(5):689-692.
15. Tabrizi SJ, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol. 2013;12(7):637-649.
16. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet. 2004;65(4):267-277.
17. Todd J, et al. Ultrasensitive flow-based immunoassays using single-molecule counting. Clin Chem. 2007;53(11):1990-1995.
18. Constantinescu R, Romer M, Oakes D, Rosengren L, Kieburtz K. Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington's disease. Parkinsonism Relat Disord. 2009;15(3):245-248.
19. DiFiglia M, et al. Aggregation of Huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 1997;277(5334):1990-1993.
20. Li H, Li S-H, Johnston H, Shelbourne PF, Li X-J. Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nat Genet. 2000;25(4):385-389.
21. Wang C-E, et al. Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease. Hum Mol Genet. 2008;17(17):2738-2751.
22. Telenius H, et al. Somatic and gonadal mosaicism of the Huntington disease gene CAG repeat in brain and sperm. Nat Genet. 1994;6(4):409-414.
23. Kennedy L, Shelbourne PF. Dramatic mutation instability in HD mouse striatum: does polyglutamine load contribute to cell-specific vulnerability in Huntington's disease? Hum Mol Genet. 2000;9(17):2539-2544.
24. Kennedy L, et al. Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. Hum Mol Genet. 2003;12(24):3359-3367.
25. Savage MJ, et al. A sensitive Aβ oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid. J Neurosci. 2014;34(8):2884-2897.
26. Esparza TJ, et al. Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol. 2013;73(1):104-119.
27. Jeromin A, Randall J, Wilson D, Blennow K, Zetterberg H. Ultrasensitive detection of neurodegenerative biomarkers in blood with the fully automated Simoa analyzer: clinical applications. Alzheimers Dementia. 2014;10(4, Supplement):P515-P516.
28. Björkqvist M, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med. 2008;205(8):1869-1877.
29. Lewczuk P, et al. Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid β peptides. Clin Chem. 2006;52(2):332-334.
30. Dalrymple A, et al. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res. 2007;6(7):2833-2840.
31. Baldo B, et al. TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in huntington's disease. Chem Biol. 2012;19(2):264-275.
32. UniProt: Swiss-Prot Database. P10636 - TAU-HUMAN. UniProt Web site. http://www.uniprot.org/uniprot/P10636. Updated July 9, 2014. Accessed February 27, 2015.
33. UniProt: Swiss-Prot Database. P07196 - NFL-HUMAN. UniProt Web site. http://www.uniprot.org/uniprot/P07196. Updated January 7, 2015. Accessed February 27, 2015.
34. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995;57(1):289-300.